HUMAN VERY LOW-DENSITY LIPOPROTEINS AND CHYLOMICRONS CAN PROTECT AGAINST ENDOTOXIN-INDUCED DEATH IN MICE

被引:283
作者
HARRIS, HW
GRUNFELD, C
FEINGOLD, KR
RAPP, JH
机构
[1] VET ADM MED CTR, DEPT SURG, 4150 CLEMENT ST, SAN DIEGO, CA 92161 USA
[2] VET ADM MED CTR, DEPT MED, SAN DIEGO, CA 92161 USA
关键词
detoxification; endotoxemia; lipoproteins; triglycerides;
D O I
10.1172/JCI114765
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Endotoxemia stimulates many physiologic responses including disturbances in lipid metabolism. We hypothesized that this lipemia may be part of a defensive mechanism by which the body combats the toxic effects of circulating endotoxin. We tested the effects of mixtures of endotoxin, lipoproteins, and lipoprotein-free plasma and determined the ability of varying concentrations of human very low density lipoproteins (VLDL) and chylomicrons, as well as low density lipoproteins (LDL) and high density lipoproteins (HDL), and of the synthetic lipid emulsion SOYACAL to prevent endotoxin-induced death in mice. This study demonstrates that the triglyceride-rich VLDL and chylomicrons, as well as cholesterol-rich LDL and HDL, and cholesterol-free SOYACAL can protect against endotoxin-induced death. Protection required small amounts of lipoprotein-free plasma, and depended on the incubation time and the concentration of lipoprotein lipid. Despite stringent techniques to prevent exogenous endotoxin contamination eight of ten duplicate VLDL preparations contained endotoxin (5,755 ± 3,514 ng endotoxin/mg triglyceride, mean ± SEM) making the isolation of endotoxin-free VLDL difficult. In contrast, simultaneous preparations of LDL and HDL were relatively free of endotoxin contamination (3 ± 3 and 320 ± 319 ng/mg total cholesterol, respectively), suggesting that the contamination of VLDL occurs in vivo and not during the isolation procedure. These observations suggest a possible role for increased triglyceride-rich lipoproteins in the host's defense against endotoxemia and infection.
引用
收藏
页码:696 / 702
页数:7
相关论文
共 45 条
[11]   SERUM LIPIDS IN INFECTION [J].
GALLIN, JI ;
KAYE, D ;
OLEARY, WM .
NEW ENGLAND JOURNAL OF MEDICINE, 1969, 281 (20) :1081-&
[12]  
GILBERT ROBERT P., 1960, PHYSIOL REVS, V40, P245
[13]  
GOULD MJ, 1985, 7 PAR DRUG ASS, P84
[14]   AN IMPROVED CHROMOGENIC SUBSTRATE ENDOTOXIN ASSAY FOR CLINICAL USE [J].
HARRIS, RI ;
STONE, PCW ;
STUART, J .
JOURNAL OF CLINICAL PATHOLOGY, 1983, 36 (10) :1145-1149
[15]   DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM [J].
HAVEL, RJ ;
EDER, HA ;
BRAGDON, JH .
JOURNAL OF CLINICAL INVESTIGATION, 1955, 34 (09) :1345-1353
[16]  
JACOB AI, 1977, GASTROENTEROLOGY, V72, P1268
[17]  
LANZAJACOBY S, 1982, ARCH SURG-CHICAGO, V117, P144
[18]   EFFECTS OF AN EXPERIMENTAL VIRAL INFECTION ON PLASMA LIPID AND LIPOPROTEIN METABOLISM [J].
LEES, RS ;
BEISEL, WR ;
BARTELLONI, PJ ;
FISER, RH .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1972, 21 (09) :825-+
[19]   LETHAL TOXICITY OF LIPOPOLYSACCHARIDE AND TUMOR-NECROSIS-FACTOR IN NORMAL AND D-GALACTOSAMINE-TREATED MICE [J].
LEHMANN, V ;
FREUDENBERG, MA ;
GALANOS, C .
JOURNAL OF EXPERIMENTAL MEDICINE, 1987, 165 (03) :657-663
[20]  
LEVIN J, 1970, J LAB CLIN MED, V75, P903